MedTrace Logo

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors

NCT06783569 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-09-09

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.

Conditions

Interventions

DRUG

JR8603

IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Sponsors & Collaborators

  • JiaRay Group

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-05-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783569 on ClinicalTrials.gov